Consequences of inhibition of plasma carboxypeptidase B on in vivo thrombolysis, thrombosis and hemostasis

Fibrinolysis and Proteolysis

Volumn 14, Issue 5, 2000, Pages 305-314

  Refino, C J ^a   DeGuzman, L ^a   Schmitt, D ^a   Smyth, R ^b   Jeet, S ^b   Lipari, M T ^b   Eaton, D ^a   Bunting, S ^a  

^a GENENTECH INC   (United States)

^b NIPPON ROCHE RESEARCH CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; CARBOXYPEPTIDASE B; CYTOKINE; ENZYME INHIBITOR; FIBRINOGEN; HEPARIN; IODINE 125; LYMPHOTOXIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; POTATO CARBOXYPEPTIDASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; ENZYME INHIBITION; FIBRINOLYSIS; HEMOSTASIS; NONHUMAN; PLASMA; PRIORITY JOURNAL; RABBIT; THROMBOSIS;

EID: 0033825322     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1054/fipr.2000.0087     Document Type: Article

References (38)

1. Hendriks D, Scharpe S, van Sande M, Lommaert MR Characterization of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 1989; 27: 277-285.
2. Hendriks D, Wang W, Scharpe S, Lommaert MP, van Sande M. Purification and characterization of a new arginine carboxypeptidase in human serum. Biochimica et Biophysica Acta 1990; 1034: 86-92.
3. Campbell W, Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun 1989; 162: 933-939.
4. Campbell W, Yonezu K, Shinohara T, Okada H. An arginine carboxypeptidase generated during coagulation is diminished or absent in patients with rheumatoid arthritis. J Lab Clin Med 1990; 115: 610-612.
5. Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel caboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-21838.
6. Wang W, Hendriks DF, Scharpe SS. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994; 269: 15937-15944.
7. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-14484.
8. Tan AK and Eaton DL. Activation and characterization of procarboxypeptidase B from human plasma. Biochem 1995; 34: 5811-5816.
9. Bajzar LM, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-16608.
10. Bajzar L, Nesheim M, Morser J, Tracy PB. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 2792-2798.
11. Nesheim ME. TAFI. Fibrinolysis & Proteolysis 1999; 13: 72-77
12. Redlitz A, Tan AK, F.aton DL, Plow F.F. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-2538.
13. Redlitz A, Nicolini FA, Malycky JL, Topol EJ, Plow EF. Inducible carboxypeptidase activity. A role in clot lysis in vivo. Circ 1996; 93: 1328-1330.
14. Broze GJ Jr, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996; 88: 3815-3823.
15. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependem. Blood 1996; 88: 2093-2100.
16. Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 1997; 78: 386-391.
17. Von dem Borne PA, Bajzar L, Meijers JC, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99: 2323-2327
18. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 14477-14482.
19. Minnema MC, Friederich P, Levi M et al. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-throinbolytic factor. J Clin Invest 1998; 101: 10-14.
20. Klement P, Liao P, Bajzar L A novel approach to arterial thrombolysis. Blood 1999; 94: 2735-2743.
21. Refino CJ, Paoni NF, Keyt BA et al. A Variant of t-PA (T103N, KHRR 296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogen. Thromb Haemost 1993; 70: 313-319.
22. Keyt BA, Paoni NF, Refino CJ et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994; 91: 3670-3674.
23. DeGuzman L, Refino CJ, Steinmetz H et al. Inhibition of tissue factor or intrinsic Xase are effective antithrombotic strategies in a new model of venous thrombosis. Thromb Haemost 1997; 78(suppl): 292 (abs).
24. Giles AR, Tinlin S, Greenwood R. A canine model of hemophilic (factor VIII:C deficiency) bleeding. Blood 1982; 60: 727-730.
25. Refino CJ, Bunting S, Hultgren B, Hotchkiss AJ. Enhancement of recombinant tissue plasminogen activator (rt-PA) induced thrombolysis in a rabbit arterio-venous shunt model by heparin or a direct thrombin inhibitor MCI. Blood 1988; 72: 373 (abs).
26. Gruss HJ. Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily. Int Clin Lab Res 1996; 26: 143-159.
27. ten Cate JW, Koopman MMW, Prins MH, Buller HR. Treatment of venous thromboembolism. Thromb Haemost 1995; 74: 197-203.
28. Salzman EW, Hirsh J, Marder VJ. Clinical use of heparin. In: Colman WR, Hirsh J, Marder JV, Salzman EW, eds. Hemostasis and thrombosis: basic principles and clinical practice, 3rd edn. Philadelphia: J.B. Lippincott, 1994; 1275-1296.
29. Weitz JI, Huboda M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391.
30. Koyoma T, Parkinson JF, Sie P, Bang NU, Müller-Bergbaus G, Preissner KT. Different glycoforms of human thrombomodulin. Their glycosaminoglycan-dependent modulatory effects on thrombin inactivation by heparin cofactor II and antithrombin III. EurJ Biochem 1991; 198: 563-570.
31. Salzman EW, Hirsh J. The epidemiology, pathogenesis, and natural history of venous thrombosis. In: Colman WR, Hirsh J, Marder JV, Salzman EW, eds. Hemostasis and thrombosis: basic principles and clinical practice. 3rd edn. Philadelphia: J.B. Lippincott; 1994; 1275-1296.
32. Jeske W, Callas DD, Fareed J, Kaiser B. A survey of animal models to develop new and novel antithrombotic agents. In: Sasahara AA, Loscalzo J, eds. New therapeutic agents in thrombosis and thrombolysis. New York: Marcel Dekker, 1997; 9-28.
33. Hovig T, Dodds WJ, Rowsell HC, Mustard JF. The transformation of hemostatic platelet plugs in normal and factor IX deficient dogs. Am J Path 1968; 53: 355-374.
34. Giles AR, Tinlin S, Brosseau L, Hoogendoorn H. In vivo studies of the role of factor VII in hemostasis. Blood 1985; 65: 1197-1200.
35. Kelley RF, Refino CJ, O'Connell MP et al. A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent. Blood 1997;89:3219-3227
36. Refino CJ, Himber J, Burcklen L, Moran P, Peek M, Suggett S, Devaux B, Kirchhofer D. A human antibody that binds to the γ-carboxyglutamic acid domain of factor IX is a potent antithrombotic in vivo. Thromb Haemost 1999; 82: 1188-1195.
37. Himber J, Kirchhofer D, Riederer M, Tschopp TB, Steiner B, Roux SP. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function. Thromb Haemost 1997; 78: 1142-1149.
38. Montoney M, Gardell SJ, Marder VJ. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model. Circ 1995; 91: 1540-1544.